Immunosignaturing can detect products from molecular markers in brain cancer.

Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alexa K Hughes, Zbigniew Cichacz, Adrienne Scheck, Stephen W Coons, Stephen Albert Johnston, Phillip Stafford
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/a08d902f933840fc864600a5e992ab5b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a08d902f933840fc864600a5e992ab5b
record_format dspace
spelling oai:doaj.org-article:a08d902f933840fc864600a5e992ab5b2021-11-18T07:12:26ZImmunosignaturing can detect products from molecular markers in brain cancer.1932-620310.1371/journal.pone.0040201https://doaj.org/article/a08d902f933840fc864600a5e992ab5b2012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22815729/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O(6)-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.Alexa K HughesZbigniew CichaczAdrienne ScheckStephen W CoonsStephen Albert JohnstonPhillip StaffordPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 7, p e40201 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Alexa K Hughes
Zbigniew Cichacz
Adrienne Scheck
Stephen W Coons
Stephen Albert Johnston
Phillip Stafford
Immunosignaturing can detect products from molecular markers in brain cancer.
description Immunosignaturing shows promise as a general approach to diagnosis. It has been shown to detect immunological signs of infection early during the course of disease and to distinguish Alzheimer's disease from healthy controls. Here we test whether immunosignatures correspond to clinical classifications of disease using samples from people with brain tumors. Blood samples from patients undergoing craniotomies for therapeutically naïve brain tumors with diagnoses of astrocytoma (23 samples), Glioblastoma multiforme (22 samples), mixed oligodendroglioma/astrocytoma (16 samples), oligodendroglioma (18 samples), and 34 otherwise healthy controls were tested by immunosignature. Because samples were taken prior to adjuvant therapy, they are unlikely to be perturbed by non-cancer related affects. The immunosignaturing platform distinguished not only brain cancer from controls, but also pathologically important features about the tumor including type, grade, and the presence or absence of O(6)-methyl-guanine-DNA methyltransferase methylation promoter (MGMT), an important biomarker that predicts response to temozolomide in Glioblastoma multiformae patients.
format article
author Alexa K Hughes
Zbigniew Cichacz
Adrienne Scheck
Stephen W Coons
Stephen Albert Johnston
Phillip Stafford
author_facet Alexa K Hughes
Zbigniew Cichacz
Adrienne Scheck
Stephen W Coons
Stephen Albert Johnston
Phillip Stafford
author_sort Alexa K Hughes
title Immunosignaturing can detect products from molecular markers in brain cancer.
title_short Immunosignaturing can detect products from molecular markers in brain cancer.
title_full Immunosignaturing can detect products from molecular markers in brain cancer.
title_fullStr Immunosignaturing can detect products from molecular markers in brain cancer.
title_full_unstemmed Immunosignaturing can detect products from molecular markers in brain cancer.
title_sort immunosignaturing can detect products from molecular markers in brain cancer.
publisher Public Library of Science (PLoS)
publishDate 2012
url https://doaj.org/article/a08d902f933840fc864600a5e992ab5b
work_keys_str_mv AT alexakhughes immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer
AT zbigniewcichacz immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer
AT adriennescheck immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer
AT stephenwcoons immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer
AT stephenalbertjohnston immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer
AT phillipstafford immunosignaturingcandetectproductsfrommolecularmarkersinbraincancer
_version_ 1718423806254514176